Temovate E en es it fr

Temovate E Brand names, Temovate E Analogs

Temovate E Brand Names Mixture

  • No information avaliable

Temovate E Chemical_Formula


Temovate E RX_link


Temovate E fda sheet

Temovate_E FDA

Temovate E msds (material safety sheet)

Temovate_E MSDS

Temovate E Synthesis Reference

No information avaliable

Temovate E Molecular Weight

466.97 g/mol

Temovate E Melting Point

195.5-197 oC

Temovate E H2O Solubility

3.86 mg/L

Temovate E State


Temovate E LogP


Temovate E Dosage Forms

Foam (0.05%) and ointment (usp 0.05%, supplied in 15 g, 30 g, and 45 g tubes)

Temovate E Indication

For short-term topical treatment of the inflammatory and pruritic manifestations of moderate to severe corticosteroid-responsive dermatoses of the scalp.

Temovate E Pharmacology

Like other topical corticosteroids, clobetasol has anti-inflammatory, antipruritic, and vasoconstrictive properties. It is a very high potency topical corticosteroid that should not be used with occlusive dressings. It is recommended that treatment should be limited to 2 consecutive weeks and therapy should be discontinued when adequate results have been achieved.

Temovate E Absorption

Topical corticosteroids can be absorbed from intact healthy skin. The extent of percutaneous absorption of topical corticosteroids is determined by many factors, including the vehicle and the integrity of the epidermal barrier. Occlusion, inflammation and/or other disease processes in the skin may also increase percutaneous absorption.

Temovate E side effects and Toxicity

Oral LD50 in rat and mouse is >3000 mg/kg. Topically applied clobetasol can be absorbed in sufficient amounts to produce systemic effects. Symptoms of overdose include thinning of skin and suppression of adrenal cortex (decreased ability to respond to stress).

Temovate E Patient Information

Temovate E Organisms Affected

Humans and other mammals